The NingLab focuses on Artificial Intelligence (AI), particularly generative AI (genAI), for Science (AI4Science), with applications in drug discovery (e.g., drug design via 2D molecular graph generation and 3D molecule shape generation, peptide generation), healthcare and medicine (e.g., drug repurposing and early onset detection for Alzheimer’s diseases, electronic health record retrieval, cancer drug selection), and Recommender Systems (e.g., sequential recommendation, recommendation based on LLMs).

The research at Ning Lab is currently funded by NSF, NLM, NIMH, NIAMS, NIGMS, NIA, NCATS, AIM-AHEAD, AWS, NEC Labs America, Regenstrief Institute and OSU President’s Research Excellence Program.

Research areas:


Active Projects:

  • Interpretable Deep Generative Models for Drug Development (NSF)
  • COVID-19 patient characterization and disease course analysis using multi-site large-scale EHR data (NIH)
  • Biomedical Computing and Informatics Strategies for Personalized Biomarker Research in Alzheimer’s Disease (NIH)
  • Computational Tools for Proteoform Identification by Top-Down Data Independent Acquisition Mass Spectrometry (NIH)

Completed Projects:

  • Computational Methods to Explore Big Bioassay Data for Better Compound Prioritization (NSF)
  • Mining Drug-Drug Interaction-Induced Adverse Effects from Health Record Databases (NSF)
  • Enhancing information retrieval in electronic health records through collaborative filtering (NIH)